Discover Insmed's innovative therapies targeting rare diseases, with approvals like Brinsupri boosting potential.

The U.S. Food and Drug Administration has approved Insmed's oral drug for a type of lung disease, the company said on Tuesday ...

William Blair initiated coverage of Insmed (INSM) with an Outperform rating. The firm believes that clinical and commercial execution with ...

Josh Brown, CEO of Ritholtz Wealth Management, joins CNBC's "Halftime Report" to detail his latest addition to his 'Best ...

Insmed (INSM) saw a significant price move of 87% over the past quarter, driven by pivotal product developments and regulatory milestones. The FDA's approval of BRINSUPRI as the first oral treatment ...

With a landmark U.S. approval  Tuesday, Insmed is making waves with a new class of drug that’s also the first to be green lit in the chronic lung disease bronchiectasis. | The FDA on Tuesday signed ...

The FDA has approved Insmed’s Brinsupri™ (brensocatib 10 mg and 25 mg tablets) as the first drug authorized to treat ...

Insmed has received FDA clearance for the first treatment for a chronic lung disease, opening the biotech up to what could be ...

Insmed's drug Brinsupri (brensocatib) has landed a double regulatory landmark win, becoming both the first marketed ...

BRIDGEWATER – Shares of Insmed, a pharmaceutical firm at the intersection of Route 202-206 and Allen Road, jumped 8% on the NASDAQ after the federal Food and Drug Administration approved the company's ...

Brinsupri, which Insmed acquired from AstraZeneca nearly a decade ago, is the first treatment for bronchiectasis that’s not ...

Insmed has claimed the distinction of becoming the first company to get FDA approval for a treatment for chronic lung disease ...